Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.96 - $23.22 $1.1 Million - $1.7 Million
-73,214 Reduced 57.53%
54,056 $1.26 Million
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $2.01 Million - $2.97 Million
127,270 New
127,270 $2.61 Million
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $624,890 - $881,317
26,739 Added 275.52%
36,444 $1.08 Million
Q1 2023

May 15, 2023

SELL
$21.91 - $32.67 $258,143 - $384,917
-11,782 Reduced 54.83%
9,705 $223,000
Q4 2022

Feb 14, 2023

SELL
$26.28 - $33.92 $548,437 - $707,876
-20,869 Reduced 49.27%
21,487 $597,000
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $148,080 - $219,698
-5,702 Reduced 11.86%
42,356 $1.3 Million
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $222,768 - $375,442
10,669 Added 28.54%
48,058 $1.41 Million
Q1 2022

May 16, 2022

BUY
$29.0 - $47.27 $679,992 - $1.11 Million
23,448 Added 168.19%
37,389 $1.2 Million
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $173,554 - $224,206
-4,075 Reduced 22.62%
13,941 $622,000
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $873,415 - $1.41 Million
18,016 New
18,016 $909,000
Q2 2021

Aug 16, 2021

SELL
$50.3 - $78.44 $1.41 Million - $2.19 Million
-27,958 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$53.8 - $81.53 $746,959 - $1.13 Million
13,884 Added 98.65%
27,958 $1.6 Million
Q4 2020

Feb 16, 2021

SELL
$36.89 - $93.56 $3.9 Million - $9.9 Million
-105,805 Reduced 88.26%
14,074 $1.18 Million
Q3 2020

Nov 16, 2020

BUY
$23.13 - $38.84 $2.53 Million - $4.25 Million
109,476 Added 1052.35%
119,879 $4.3 Million
Q2 2020

Aug 14, 2020

BUY
$16.01 - $28.82 $166,552 - $299,814
10,403 New
10,403 $252,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.